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Abstract 
Background: Autoimmune pancreatitis (AIP) is a form of chronic pancreatitis defined by a 
characteristic lymphoplasmacellular infiltrate, fibrosis and epithelial destruction. This 
pathology results in enlargement of the pancreas and creates a mass that mimics pancreatic 
ductal adenocarcinoma (PDAC). The distinction between this benign disease and pancreatic 
cancer can therefore be challenging, and due to the completely different treatment, differential 
diagnosis is of enormous clinical relevance. In this retrospective study, we analyze the role of 
serum gelatinases as part of the clinical strategy for the preoperative differentiation between 
AIP and PDAC. The finding of differential markers will prevent unnecessary surgical 
resection and allow optimal treatment of these pathologies. 
  
Methods: Quantitative gelatin-zymography and sandwich enzyme linked immunosorbent 
assays were applied to analyze all individual gelatinase forms in serum, and to define 
alterations associated with AIP and PDAC, and to identify cut-off values indicative for the 
diseases. Sera of 130 patients, 29 AIP, 33 CP, 32 PDAC, and 36 healthy controls, were first 
analyzed for all individual gelatinase forms by gelatin zymography prior to further 
quantitative analysis by ELISA.  
Results: Serum profiling data obtained by zymography analysis revealed that gelatinase-
B/MMP-9, the NGAL-MMP-9 complex and gelatinase A/MMP-2 were significantly 
increased in AIP patients, indicating that these proteins are promising markers to discriminate 
between AIP and PDAC. With ELISA we confirmed the zymography results and the 
quantitative assessment of the proteins levels. 
Conclusions. MMP serum profiles as AIP markers, together with other clinical tests, help to 
assure the diagnosis of PDAC or AIP. 
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Introduction 
Autoimmune pancreatitis (AIP) is a distinct clinical entity, described as a chronic 
inflammatory process of the pancreas with autoimmune mechanisms. Clinically and 
histologically two subsets of autoimmune pancreatitis (type 1 and type 2 AIP) exist and 
should be distinguished. 
1,2
. The type 1 AIP is a lymphoplasmacytic sclerosing pancreatitis 
(LPSP) and shows some typical features: periductal lymphoplasmacytic infiltrate, fibrosis, 
(obliterative) venulitis, and infiltrates of IgG4-positive plasma cells. Type 1 AIP presents 
several serological characteristics, the most prominent being elevated serum levels of IgG4 
which is crucial for diagnosis in absence of histology according to the Mayo HISORt criteria. 
3
 Nevertheless, the application of IgG4 as a diagnostic parameter is not satisfactory because 
up to 50% of AIP patients have normal IgG4 levels (cut off <1.4 g/L) and elevated IgG4 are 
also reported in other pancreatic diseases including PDACs. Aside from elevated IgG4, 
antinuclear antibodies, anticarbonic anhydrase and antilactoferrin secretory trypsin can also be 
increased.  
Type 2 AIP idiopatic duct-centric pancreatitis (IDCP) is characterized by massive infiltration 
of granulocytes in the pancreatic parenchyma and ductal epithelial lesions (GEL). These 
distinct ductal lesions may extend into the ductules, acini, and interstitial spaces. In this 
subtype the walls of the pancreatic ducts are usually infiltrated by neutrophils, lymphocytes, 
and plasma cells. This pathomorphological change has first been described by Ectors et al. 
and is characterized by focal detachment, disruption and destruction of the epithelium of 
interlobular ducts due to invading neutrophilic and occasionally eosinophilic granulocytes 
4
. 
The massive infiltrate of neutrophils followed by their degranulation results in extensive 
liberation of host defense proteins including gelatinase B (also named MMP-9) and neutrophil 
gelatinase B-associated lipocalin (NGAL)
5
. These proteins form a covalent linkage called 
NGAL-MMP9-complex. NGAL was reported to be overexpressed in pancreatic cancer 
6
. 
Terris et al identified NGAL as a marker for intraductal papillary mucinous neoplasm (IPMN) 
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a precursor lesion leading to invasive carcinoma 
7
. The expression of NGAL was also found 
in various grades of pancreatic intraepithelial neoplasia (PanIN) including the PanIN-1 stage 
lesion and was suggested as the marker of the earliest premalignant changes in the pancreas 
8
. 
The function of the NGAL-MMP-9 complex is not yet fully elucidated. However, it was 
proposed that MMP-9 bound to NGAL is protected from autodigestion or alternatively that 
NGAL supports an allosteric activation of pro-MMP-9 
9,10
.  
Matrix metalloproteases are major factors that degrade the extracellular matrix. The 
gelatinases, a subfamily composed of MMP-2 (gelatinase A) and MMP-9 (gelatinase B), were 
originally distinguished for the ability to digest denatured collagens or gelatines. Later, it was 
discovered that they also process a wide range of other extracellular (e.g. components 
basement membranes and cytokines), pericellular (e.g. occludings and intercellular adhesion 
molecules) and intracellular (e.g. heat shock proteins and cathepsins) substrates 
11-13
. The 
degradation of basement membranes and extracellular matrix plays a key role in the severity 
of inflammation and tumor progression. Overexpression of MMP-2 and MMP-9 in pancreatic 
cancer was previously reported 
14,15
, and the gelatinases were also investigated as differential 
markers for CP and PDAC 
16-18
.  
In acute pancreatitis, high MMP-9 levels were found in neutrophils. In chronic pancreatitis 
the major source are ductal epithelial cells. MMP-9 cleaves secreted insulin and the resulting 
insulin-degradation products, so-called remnant epitopes generating autoimmunity (REGA), 
are presented to autoreactive T cells that trigger autoimmunity and aggravate diabetes by loss 
of β cells 19. The role of extracellular proteolysis in innate and adaptive immunity and the 
interplay between cytokines, chemokines, and proteinases are recently recognized as critical 
factors in autoimmune processes 
20
. 
The diagnosis of AIP is made mainly based on clinical, radiologic, and laboratory findings. 
However, to differentiate AIP from PDAC can often be very challenging as the patient 
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demographics and the presenting clinical and imaging features (e.g. pancreatic enlargement, 
obstructive jaundice in 76%, weight loss in 35% of patients) are often similar. Consequently, 
affected patients are frequently referred for surgery and undergo pancreatic resection to 
exclude the risk of pancreatic cancer. Recognizing AIP through e.g. serologic markers is 
crucial as about 2.5-11 % of patients undergoing surgery for possible PDAC are discovered to 
have a benign inflammatory disease of the pancreas 
21-23
. AIP can be treated by steroids and a 
high response to corticosteroids therapy is an important diagnostic criterion. Therefore it is 
extremely important to diagnose AIP to choose the appropriate treatment and avoid 
unnecessary surgery. 
The aim of this study was a comparative analysis to define alterations of gelatinases by 
applying a combinatory approach of zymography and ELISAs on serum samples of patients 
with AIP, CP, PDAC and to investigate whether altered MMP serum levels allow clinicians to 
discriminate AIP from PDAC. 
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Materials and Methods 
Samples 
Patients’ blood samples were prospectively collected between January 2006 and March 2012 
obtained during surgery at the Department of Surgery, University of Heidelberg. All sera 
were obtained according to a standardized sampling and coding protocol 
24
. 
In total, 130 preoperative serum samples were selected from patients diagnosed with 
adenocarcinoma of the pancreas (PDAC, 32 samples), alcoholic chronic pancreatitis (CP, 33 
samples), autoimmune pancreatitis (AIP, 29 samples) and a healthy control group (Co, 36 
samples). The diagnosis of PDAC, CP or AIP was confirmed by histopathology. In case of 
AIP the Mayo Clinic (HISORt) criteria were used 
3
. The histological examination of formalin 
fixed, paraffin embedded and H&E stained pancreatic tissue sections was performed by 
pathologist MMG at the Pathology Department University of Heidelberg. The study was 
approved by the ethics committee of the University of Heidelberg, and a written informed 
consent was obtained from all patients. Patient demographics and clinical data for the four 
investigated groups are summarized in table 1. 
 
Gelatin zymography 
Prior to gelatin zymography analysis, all samples were pre-purified by gelatin-affinity 
chromatography as described previously 
25
. Briefly, each sample was loaded onto a Micro 
Bio-Spin Chromatograhy Column (Bio-Rad, CA, USA) containing Gelatin-Sepharose 4B 
beads (GE Healthcare, Buckinghamshire, UK) in equilibration buffer (50 mM Tris pH 7.5, 0.5 
M NaCl, 10 mM CaCl2, 0.01% Tween 20). As an internal reference, 500 pg of recombinant 
human proMMP-9ΔOGHem was added to each sample and this mixture was incubated for 20 
min at room temperature. Next, the samples were treated three times with washing buffer 1 
(50 mM Tris pH7.5, 0.5 M NaCl, 10 mM CaCl2, 0.05% Tween-20). After one additional wash 
 7 
in buffer 2 (50 mM Tris pH 7.5, 10 mM CaCl2, 0.05% Tween-20), the samples were eluted in 
20 µl non-reducing loading buffer (0.125 M Tris pH 6.8, 4% SDS, 0.01% bromophenol blue, 
20% glycerol).  
The prepurified samples were loaded onto 7.5% polyacrylamide gels which contained 0.1% 
gelatin. After electrophoresis the gels were removed from the electrophoresis system and 
washed twice for 20 minutes with 2.5% Triton X-100. Next, the gels were incubated 
overnight at 37°C in incubation buffer (50mM Tris-HCl, pH 7.5, 10mM CaCl2, 1% Triton X-
100) to allow gelatin degradation. Finally, the gels were stained with a PhastGel Blue R-350 
staining kit (GE Healthcare, Piscataway, NJ, USA) and the densities of the individual bands 
were analyzed with the ImageQuant TL software (GE Healthcare, Piscataway, NJ, USA) 
5,13
.  
The concentrations of proMMP-2, MMP-2, the NGAL-MMP-9 complex, proMMP-9, MMP-9 
and MMP-9 multimers were calculated based on the density of the bands, the recovery of the 
internal reference after co-prepurification and a dilution series of recombinant wild-type 
MMP-9 of known concentrations. MMP-9ΔOGHem and wild-type MMP-9 have been 
described 
26
.  
 
Immunoassays for Biomarker Quantitation 
For quantitative determination of the human NGAL-MMP-9 complex and MMP-2, solid 
phase capture sandwich ELISAs were performed using commercially available kits: NGAL-
MMP-9 Complex Quantikine, MMP-2 Quantikine and total MMP-2 Quantikine (all from 
R&D Systems, Abingdon, UK). With the NGAL-MMP-9 ELISA, the presence of the NGAL-
MMP-9 complex is measured by using antibodies against recombinant human MMP-9 and 
recombinant human NGAL.  Free MMP-9 or NGAL are not detected. With the MMP-2 kit 
the complexes of active MMP-2 are not detected. With the total MMP-2 kit, proMMP-2, 
activated MMP-2 and TIMP-bound MMP-2 are measured. As capturing antibody a 
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monoclonal Ab specific to MMP-2 and a HRP-linked polyclonal Ab specific to MMP-2 were 
used. Prior to the ELISAs, all sera were 1:20 diluted and the ELISAs were performed 
according to manufacturer’s protocols. The optical density was measured with a microplate 
ELISA reader (Multiscan EX, Thermo Electron Corporation, USA) at  = 450 nm with 
wavelength correction 450-570 nm. For the analysis of human interleukin 17 (IL-17) 
concentrations in sera of the four cohorts, a commercial sandwich IL-17 ELISA kit was 
purchased from R&D and the assay was carried out according manufactures protocol.   
 
Biometric analysis 
Statistical analysis and graphical data presentation were performed using GraphPad Prism 5 
(GraphPad software Inc., San Diego, CA). The quantitative variables are presented as bars 
showing the median and interquartile range (IQR). The significance of differences between 
groups was assessed using non-parametric methods including Mann-Whitney tests for two 
groups and Kruskal-Wallis with Dunn’s tests for multiple groups. Biometric analysis was 
performed to examine the strength of correlation between the gelatin zymography of NGAL-
MMP-9 and MMP-2 markers with levels of ELISA-based validations of the proteins. 
Depending on the character of the distributions of the quantitative parameters in each group 
the correlation coefficient r with its corresponding p-value of Pearson and Spearman were 
used to analyse the correlations.  
 
 
 
 
Results 
Serum gelatinase expression profiling 
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First, we evaluated the serum levels of various gelatinase forms by quantitative gelatine 
zymography. We analysed sera from 29 AIP, 33 CP, 32 PDAC patients and 36 healthy 
controls. The plots of individual gelatinase-forms found in the four cohorts are presented in 
Figure 1.a-f. The zymography analysis revealed significantly higher levels of proMMP-9 in 
AIP, compared to PDAC (p = 0.005, Fig 1b). Additionally, the levels of the NGAL-MMP-9 
complex were significantly elevated in AIP versus PDAC (p = 0.003, Fig 1 d). For the MMP-
9 multimers and for the activated MMP-9 form significantly higher levels were found in CP p 
= 0.004 and p = 0.01 respectively, but not for its subform AIP in comparison to PDAC (Fig. 
1a,c). The zymography analysis for gelatinase A (MMP-2) showed also significant higher 
levels in AIP comparing to PDAC (p< 0.001) Fig. 1f. Overall, low levels of activated MMP-2 
were detected and although these seemed elevated in AIP, no statistical significance was 
obtained. Further zymography analysis of the two AIP subtypes revealed no significant 
differences in individual gelatinases forms between AIP type-1 and AIP type 2 results not 
shown. 
 
Validation of zymography analysis 
To evaluate the diagnostic accuracy of the gelatinase forms found by zymography we 
measured serum levels of the NGAL-MMP-9 complex (Fig. 2a), MMP-2 (which exclude the 
the complexes of active MMP-2) Fig. 2b and total-MMP-2 (Fig. 2c) by commercially 
available sandwich ELISAs in a cohort of the 29 AIP, 30 PDAC, and 30 normal randomly 
picked samples. With these assays we were also able to discriminate the AIP sera from the 
PDAC group and confirmed the zymography data. Figure 3 shows the correlation plots of the 
protein analysis with both techniques for each group. A strong correlation was found between 
the two assays (zymography and ELISA) of the NGAL–MMP-9 complex from patients with 
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AIP ( Pearson correlation coefficient r = 0.7009, p < 0.0001; r
2
 = 0.49), b; from patients with 
PDAC  (Pearson r = 0.90, p < 0.0001; r
2
 = 0.81) (Fig. 3). 
 
IL17-serum levels 
Next, we further explored the possible reason for finding elevated serum levels of proMMP-9 
and NGAL-MMP-9 complex. Recent publications suggest that IL-17 is an initial trigger for 
activated PMNs 
27
. Infiltration in AIP-tissue by IL-17+ cells was recently demonstrated 
28
. 
Therefore we evaluated the levels of IL-17 in our cohorts of CP, AIP and PDAC patients (Fig. 
4). As expected, slightly elevated IL17-serum levels were found in our investigated cohorts. 
In agreement with recent publications 
29
, our data support the notion that IL-17 production is 
required for the initiation and progression of early PDAC.  
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Discussion 
Some studies denominate that about 5-11% of the patients undergoing surgery for pancreatic 
cancer are finally diagnosed with a “benign” pancreatitis of which one-third is diagnosed with 
AIP
30-32
.  For this reason, it is necessary to find and develop clinically applicable and non-
invasive approaches such as serum biomarkers or imaging to distinguish AIP from PDAC. 
In the present study we used a combinatory approach of multi-analyte quantitative gelatin 
zymography to define alterations in the variety of molecular forms of serum gelatinases in 
AIP and PDAC, and compared their serum levels to chronic pancreatitis and a healthy control 
cohort. In the quantitative zymography technique every sample is spiked with a known 
amount of a gelatinase form that is processed at a different position from the analytes. In our 
case we used a recombinant human gelatinase B deletion mutant without hemopexin and o-
glycosylated domain 
26
. A major goal was to evaluate the potential of the MMP-2/gelatinase 
A and MMP-9/gelatinase B forms as marker-candidates to differentiate benign and malignant 
pancreatic diseases. Serum gelatinase profiling data obtained by zymography analysis 
revealed that MMP-9, also in its complexed form with neutrophil gelatinase associated 
lipocalin (NGAL-MMP-9-complex), was significantly increased in AIP patients, indicating 
that both protein forms are promising markers to discriminate between AIP and PDAC. 
Previously the NGAL-MMP-9 complex has also been found to constitute an excellent 
biomarker for ulcerative colitis 
33
. In addition to MMP-9 also MMP-2 levels in AIP sera were 
significantly elevated. Gelatin zymography, though a laborious method, has the big advantage 
first, to assess multiple analytes simultaneously (MMP-2, MMP-9 mono, and multimeres, 
NGAL-MMP-9 complex) and also to decipher the decomposed forms of these proteolytic 
enzymes. Therefore the gained information is richer than that of a single parameter. A 
disadvantage of conventional commercially available ELISAs is that all these molecules are 
measured as a mixture of monomers, multimers, activated forms, degradation products and 
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complexes, without information about single molecular species 
5,13
. Our approach is therefore 
more reliable than conventional serum analyses. 
In one of our previous studies, applying 2D-DIGE, we screened AIP and PDAC patients’ sera 
for significant distinctive changes of proteins. We found in sera of AIP patients higher 
concentration of apolipoproteins A-I, apolipoprotein A-II, and transthyretin, whereas 
haptoglobin revealed lower levels in the AIP group 
34
. These significant differences in 
individual proteins, are not only of diagnostic relevance, moreover indicate a different 
aetiology of AIP and PDAC.  
By applying sandwich ELISAs we confirmed the zymography results and the quantitative 
assessment of the proteins and both assays revealed a strong correlation. Here we report for 
the first time that MMP-9 and its NGAL-complexed form are good candidate markers for 
differential diagnose of PDAC and AIP.  
The elevated expression of NGAL has been reported in benign and malign diseases including 
pancreatic diseases. Based on observations of high expression of NGAL in early dysplastic 
lesions in the pancreas, Moniaux et al. suggested this protein as possible early diagnostic 
marker for pancreatic cancer. They also reported on significantly elevated serum NGAL 
levels in both pancreatitis and PDAC. Because they did not find significant difference 
between the NGAL serum levels in pancreatitis versus pancreatic cancer, they assumed that 
serum NGAL levels alone are inadequate to distinguish pancreatic cancer from chronic or 
acute pancreatitis 
8
. We were able to demonstrate that proMMP-9 and the NGAL-MMP-9 
complex are valid markers for differential diagnosis. The reason for elevated serum proMMP-
9 and NGAL-MMP-9 complex form is not elucidated but recent data indicate IL-17 being a 
potential initial trigger. Infiltration of AIP-tissue by IL-17+ cells was recently demonstrated 
28
. The slightly elevated IL17-serum levels in our investigated cohorts of CP, AIP, and PDAC 
support this possibility (Fig. 4). The working hypothesis could be in the signal sequence that 
 13 
Il-17 induces IL-8/CXCL8 and related neutrophil chemokines (GCP-2/CXCL6) and this 
recruits neutrophils and the further  of release the NGAL-MMP-9 complex from these cells 
35,36
. It is also accumulating evidence that IL-17 is deeply involved in inflammatory processes 
and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematous, and 
systemic sclerosis 
37,38
. Additionally, Mc Allister et al. recently demonstrated that IL-17 
production is required for the initiation and progression of precursor lesions to PDAC. 
Moreover, inhibition of the IL-17 signaling effectively prevented the initiation of pancreatic 
neoplasia 
29
.   
The present results together with our previous findings, could form the basis for a combined 
and clinically applicable blood test, allowing a reliable distinction between AIP and PDAC. 
This test would warrant AIP patients an immune-suppressive therapy without surgery and 
PDAC patients an immediate surgical- and chemotherapeutical treatment. Wrong treatment of 
these modalities results in loss of precious time for cancer patients to obtain the right therapy 
and, on the other hand, AIP patients to undergo a huge operation, which is not necessary for 
this condition.  
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Legends to the figures 
Figure 1: Zymography analysis of serum gelatinases in CP, AIP, PDAC and healthy controls 
(Co). a; MMP-9 multimers, b; proMMP-9, c; MMP-9, d; NGAL-MMP-9 complex, e; MMP-
2, f, proMMP-2. Values are shown as a median, 25th and 75
th
 percentiles and are expressed in 
nanomolar. 
 
Figure 2: ELISA. Serum levels of the NGAL-MMP-9 complex (a), MMP-2 (b) and total 
MMP-2 (c). Values are shown as mean with SEM and are expressed in mg protein/ml serum. 
 
Figure 3: Correlation plots of the serum NGAL–MMP-9 complex levels as measured by 
sandwich ELISA and zymography. a; from patients with AIP (Pearson correlation coefficient 
r = 0.7009, p < 0.0001; r
2
 = 0.49), b; from patients with PDAC (Pearson r = 0.90, p < 0.0001; 
r
2
 = 0.81) 
 
 
Figure 4: Serum IL-17 levels in CP, AIP, PDAC and healthy controls (Co). IL-17 was 
significantly upregulated in PDAC, compared to healthy controls (p = 0.009) and patients 
with chronic pancreatitis (p = 0.018). 
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Table 1: Patients data  
 
Cohort AIP total AIP type 1 AIP type 2 PDAC CP Control 
Patients (n) 29 19 10 32 33 36 
 Age (y)* 51(37-75) 58 (42-75 )  63 (46-80 ) 48 (25-70 ) 31 (15-64 ) 
Gender m/f 26/3 19/0 7/3 23/9 20/13 16/20 
Panc.surgery 21 11 10 32 33 0 
CA 19.9 U/ml* 5.7 (0.9-217) 2.7 (0.9-217) 7.0 (0.9-15.2) 79(9-2316) 10,9 (5,6-742) n.d. 
CA 19.9 >37U/ml (n) 2 2 0 14 4 n.d. 
IgG > 16g/L (n) 4 4 0 n.d. n.d. n.d. 
IgG4>1.4g/L (n) 16 14 2 n.d. n.d. n.d. 
CRP>5mg/L (n) 8 5 3 21 11 n.d. 
 
*Median (min-max); n.d.: not determined 
Table1
